INT197766

Context Info Confidence 0.32 First Reported 2006 Last Reported 2009 Negated 0 Speculated 0 Reported most in Body Documents 5 Total Number 5 Disease Relevance 1.60 Pain Relevance 0.25

enzyme regulator activity (Sln)

Anatomy Link Frequency SLN 1 Sln (Rattus norvegicus)

Pain Link Frequency Relevance Heat Inflammation 9 93.80 Bioavailability 14 88.08 transdermal 18 75.00 imagery 2 63.80 anesthesia 3 59.84 Pain 2 5.00 Neuritis 1 5.00 cINOD 1 5.00 carrageenan induced 1 5.00 rheumatoid arthritis 1 5.00

Disease Link Frequency Relevance Heat Melanoma 45 99.80 Metastasis 29 99.44 Diabetes Mellitus 12 97.24 Cutaneous Melanoma 7 96.04 Pressure And Volume Under Development 7 95.56 INFLAMMATION 9 93.80 Disease 1 62.80 Cancer 10 59.16 Nevus 5 5.00 Toxicity 3 5.00

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

The amount of drug bound to the SLN was found to increase with the increase in the stearic acid concentration and this may be due to the higher intactness of the lipid.

SLN Binding (bound) of

1) Confidence 0.32 Published 2008 Journal Indian Journal of Pharmaceutical Sciences Section Body Doc Link PMC2792476 Disease Relevance 0 Pain Relevance 0

Both the SLN and NLC dispersions and gels enriched with SLN and NLC possessed a sustained drug release over period of 24 h but the sustained effect was more pronounced with the SLN and NLC gel Background

SLN Binding (enriched) of

2) Confidence 0.32 Published 2009 Journal Lipids Health Dis Section Abstract Doc Link PMC2651881 Disease Relevance 0.19 Pain Relevance 0.15

The reduction of the initial glucose levels versus time after intragastric insulin-loaded SLN, insulin solution and subcutaneous administration of insulin is depicted in Figure 2.

SLN Binding (intragastric) of

3) Confidence 0.24 Published 2007 Journal International Journal of Nanomedicine Section Body Doc Link PMC2676823 Disease Relevance 0.10 Pain Relevance 0.03

SLN characterization

SLN Binding (characterization) of

4) Confidence 0.24 Published 2007 Journal International Journal of Nanomedicine Section Body Doc Link PMC2676823 Disease Relevance 0.07 Pain Relevance 0

Thus, prevailing evidence supports the evaluation of SLN for melanoma metastases as the standard of care to identify subset of patients with metastases in cutaneous melanoma.

SLN Binding (evaluation) of in SLN associated with melanoma, cutaneous melanoma and metastasis

5) Confidence 0.07 Published 2006 Journal Diagn Pathol Section Body Doc Link PMC1592125 Disease Relevance 1.25 Pain Relevance 0.06

General Comments

This test has worked.